Halozyme Therapeutics, Inc.
HALONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for HALO. That does not mean none is planned.
Get an email about HALO's next catalysts
Track Halozyme Therapeutics (HALO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment. The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.
WebsiteNivolumab + Relatlimab
Melanoma
Hylenex
Pain
Mitomycin C
Bladder Cancer
Humalog
Type 1 Diabetes Mellitus
PEGPH20
Metastatic Pancreatic Cancer
rHuPH20
Dermatitis, Allergic Contact
regular human insulin
Diabetes Mellitus, Type 1
Insulin lispro
Diabetes Mellitus, Type 1
CINRYZE with rHuPH20
Hereditary Angioedema
Recombinant human hyaluronidase PH20
Diabetes Mellitus, Type II
Recombinant human hyaluronidase PH20 (rHuPH20)
Diabetes Mellitus, Type 2
Humulin-R
Diabetes Mellitus, Type 2
Chemophase
Bladder Cancer
Insulin aspart
Diabetes Mellitus, Type II
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nivolumab + Relatlimab | Phase 3 | Melanoma | - | - |
Hylenex | Phase 3 | Pain | - | - |
Mitomycin C | Phase 2 | Bladder Cancer | - | - |
Humalog | Phase 2 | Type 1 Diabetes Mellitus | - | - |
PEGPH20 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
rHuPH20 | Phase 2 | Dermatitis, Allergic Contact | - | - |
regular human insulin | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Insulin lispro | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
CINRYZE with rHuPH20 | Phase 2 | Hereditary Angioedema | - | - |
Recombinant human hyaluronidase PH20 | Phase 2 | Diabetes Mellitus, Type II | - | - |
Recombinant human hyaluronidase PH20 (rHuPH20) | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Humulin-R | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Chemophase | Phase 2 | Bladder Cancer | - | - |
Insulin aspart | Phase 2 | Diabetes Mellitus, Type II | - | - |
Frequently asked questions
What is in Halozyme Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 14 drug candidates in Halozyme Therapeutics, Inc.'s (HALO) pipeline across Phase 3, Phase 2. Its lead program is Hylenex (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Halozyme Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Halozyme Therapeutics, Inc. (HALO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HALO biotech catalysts?→
Add HALO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Halozyme Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.